Peripheral neuropathies under Immune Checkpoint Inhibitors: A pharmacovigilance study

被引：0
|
作者：
Ewig, E. [1 ]
Fournier, D. [1 ]
Palassin, P. [2 ]
Cholle, C. [3 ]
Bihan, B. [1 ]
Lebrun-Vignes, B. [1 ]
机构：
[1] GH Sorbonne Univ, Dept Pharmacol, Ctr Reg Pharmacovigilance Pitie St Antoine, AP HP, Paris, France
[2] CHU Montpellier, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale & Toxicol, Montpellier, France
[3] CHU Bordeaux, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale, Pole Sante Publ, Bordeaux, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
immune checkpoint inhibitors; peripheral neuropathy; pharmacovigilance;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-043
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [41] Combination of immune checkpoint inhibitors plus chemotherapy and risk of pneumonitis: A worldwide retrospective pharmacovigilance study.
    Zheng, Yi-Fan
    Xu, Pei-Hang
    Li, Zi-Mu
    Kuang, Yu-Kun
    Li, Jia
    He, Jun-Hao
    Chen, Xiao
    Tang, Ke-Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis"
    Noguchi, Yoshihiro
    Yan, Miao
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 238 - 239
  • [43] Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
    Nguyen, Lee S.
    Raia, Lisa
    Lebrun-Vignes, Benedicte
    Salem, Joe-Elie
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [44] Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
    Bomze, David
    Meirson, Tomer
    Ali, Omar Hasan
    Goldman, Adam
    Flatz, Lukas
    Habot-Wilner, Zohar
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (01) : 191 - 197
  • [45] Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS
    Xi, Xin
    Yan, Xida
    Chen, Ying
    Li, Wenjun
    Dong, Jie
    Ou, Xuan
    Tan, Haowen
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [46] IMMUNE CHECKPOINT INHIBITORS AND THE RISK OF ATRIO-VENTRICULAR BLOCK - A PHARMACOVIGILANCE ANALYSIS
    Gudiwada, Mohan Chandra Vinay Bharadwaj
    Sahni, Ankit
    Sam, Riya Mary
    Gaddam, Vinuthna
    Jasti, Jaswanth
    Sreemantula, Harsha Sai
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2206 - 2206
  • [47] Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
    Diaz, Laurine
    Jauzelon, Benjamin
    Dillies, Anne-Charlotte
    Le Souder, Cosette
    Faillie, Jean-Luc
    Maria, Alexandre Thibault Jacques
    Palassin, Pascale
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
  • [48] Biliary toxicity of immune checkpoint inhibitors: A pharmacovigilance study through FDA adverse event reporting system database
    Guo, Qixiang
    Lu, Wenchao
    Wang, Tiansheng
    Zhao, Zhixia
    Liu, Lihong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 157 - 157
  • [49] Stress Cardiomypoathy in the Patient on Immune Checkpoint Inhibitors; a Pharmacovigilance Study From 2013-2023 FAERS Database
    Alwifati, Nader
    Daloub, Shaden
    Faisaluddin, Mohammed
    Mohamed, Mohamed Salah
    Abosbeta, Mohamed
    Al-Ali, Omar
    Iqbal, Uzma
    CIRCULATION, 2023, 148
  • [50] Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
    Chen, Xi
    Wu, Wanchun
    Wei, Wenwen
    Zou, Liqun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345